Nasopharyngeal type undifferentiated carcinoma

Summary

Nasopharyngeal type undifferentiated carcinoma (MONDO:0003572) is a cancer and 6 clinical trials. Top therapeutic interventions include becotatug vedotin. A subtype of large cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	nasopharyngeal type undifferentiated carcinoma
Mondo ID	MONDO:0003572
DOID	DOID:5660
NCIT	C4107
UMLS	C0334254
MedGen	87199
Is cancer (heuristic)	yes

Also known as: lymphoepithelial carcinoma · lymphoepithelioma · lymphoepithelioma-like carcinoma · nasopharyngeal type undifferentiated carcinoma · Schmincke tumor · Schmincke tumour · Schminke tumor · Schminke tumour

Disease family

This is a subtype of large cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › large cell carcinoma › nasopharyngeal type undifferentiated carcinoma

Related subtypes (4): lung large cell carcinoma, large cell neuroendocrine carcinoma, salivary gland large cell carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma

Subtypes (3): cervical lymphoepithelioma-like carcinoma, lymphoepithelioma-like thymic carcinoma, infiltrating bladder lymphoepithelioma-like carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	3
Not specified	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06969534	PHASE2	RECRUITING	Safety and Efficacy of Pucotenlimab in pLECC
NCT07584499	PHASE1	RECRUITING	Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
NCT00062868	PHASE1	COMPLETED	LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
NCT01956084	PHASE1	COMPLETED	Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma
NCT04430166	Not specified	UNKNOWN	PD-1 Monoclonal Antibody in Pre-treated Lymphoepithelioma-like Carcinoma
NCT04614818	Not specified	UNKNOWN	A Multi-center, Retrospective Analysis of Clinical Character, Outcome and Prognosis of Lymphoepithelioma-like Carcinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BECOTATUG VEDOTIN	3	1